Tiamat Sciences is a technology company.
Tiamat Sciences has raised $5.0M across 2 funding rounds.
Tiamat Sciences has raised $5.0M in total across 2 funding rounds.
Tiamat Sciences is a biotechnology company founded in 2019 that manufactures animal-free proteins, including growth factors, antigens, and enzymes, using a proprietary plant molecular farming platform combining biotechnology, vertical farming, and computational design.[1][2][4] It serves industries like cellular agriculture (for cheaper cultured meat production), regenerative medicine, and vaccine manufacturing by producing cost-effective reagents in plants as bioreactors, replacing expensive animal-derived or bioreactor-based alternatives.[2][3][4] The company has raised $5.4 million in total funding, including a $3 million seed round in 2021 led by True Ventures, and achieved a milestone in May 2024 by expressing T7 polymerase—an enzyme critical for mRNA vaccine production—demonstrating strong growth momentum toward commercialization.[1][2][3]
Headquartered in Durham, North Carolina (after relocating from Belgium), Tiamat operates with under 25 employees and revenue below $5 million, focusing on scaling to carbon-neutral pilot production while developing its first products for customer testing.[1][2]
Tiamat Sciences was founded in 2019 by CEO France-Emmanuelle Adil, who launched the company initially in Belgium to address the high costs of biomolecule production for cellular meat and beyond.[2] Adil's vision emerged from recognizing that traditional bioreactors and animal-sourced proteins were inefficient and expensive; she pioneered a plant-based molecular farming approach to produce recombinant proteins more affordably.[1][2] Early traction included a small pre-seed round in July 2020, followed by a $3 million seed in November 2021 led by True Ventures (with Social Impact Capital and Cantos), bringing total funding to $5.4 million.[1][2]
A pivotal moment came in May 2021 when the company relocated its headquarters to Durham, North Carolina, to expand operations and build a pilot facility, aligning with U.S. biotech hubs for faster scaling.[2] This move supported technology development and plans for rapid growth, including partnerships for large-scale plant deployment.[2]
Tiamat Sciences rides the wave of sustainable biotech and alternative proteins, fueled by demand for animal-free reagents in the $20+ billion cultured meat market and mRNA therapeutics post-COVID.[2][3] Timing is ideal amid rising bioreactor costs, supply chain vulnerabilities for animal-sourced proteins, and investor interest in plant-based manufacturing—exemplified by its 2021 seed from True Ventures' plant-based portfolio.[2] Market forces like regulatory pushes for sustainable food tech and vaccine scalability favor its platform, which could democratize access to expensive biomolecules.[1][2][3]
By enabling cheaper, greener production, Tiamat influences the ecosystem, potentially accelerating cultured meat commercialization, expanding mRNA toolkits, and inspiring hybrid farming-biotech models in agtech.[2][4]
Tiamat Sciences is poised for expansion with its validated T7 polymerase breakthrough and pilot facility, likely securing partnerships and larger funding for commercial-scale production by 2026.[2][3] Trends like precision fermentation advancements and climate-driven protein alternatives will propel its growth, evolving it from niche reagent maker to key supplier in biotech supply chains. As plant-based platforms mature, Tiamat could redefine affordable biomanufacturing, amplifying its role in feeding global needs for ethical, scalable proteins—building directly on its mission to reinvent recombinant production.[1][2]
Tiamat Sciences has raised $5.0M in total across 2 funding rounds.
Tiamat Sciences's investors include 8090 Industries, Breakthrough Energy Ventures, CoinFund, ParaFi Capital, Pioneer Fund, Robot Ventures, SID Venture Partners, Solana Ventures, Team Global, True Ventures, Stani Kulechov, Stefan George.
Tiamat Sciences has raised $5.0M across 2 funding rounds. Most recently, it raised $2.0M Seed in March 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2023 | $2.0M Seed | 8090 Industries, Breakthrough Energy Ventures, CoinFund, ParaFi Capital, Pioneer Fund, Robot Ventures, SID Venture Partners, Solana Ventures, Team Global, True Ventures, Stani Kulechov, Stefan George, Tegan Kline, Tyler Scott Ward | |
| Nov 1, 2021 | $3.0M Seed | CoinFund, ParaFi Capital, Pioneer Fund, Robot Ventures, SID Venture Partners, Solana Ventures, True Ventures, Stani Kulechov, Stefan George, Tegan Kline, Tyler Scott Ward |